Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.

This study demonstrated a validated UPLC method for analyzing finasteride in low-dose drug products, highlighting methanol content and flow rate as critical factors for method robustness and accuracy.

In this study, finasteride dose-dependently inhibited stress-induced increases in allopregnanolone in rats, while enhancing 20alpha-reduction of progesterone without affecting 3alpha-dihydroprogesterone or 11-deoxycorticosterone levels.

In this study, female rats given high doses of testosterone showed decreased endometrial thickness and lower mRNA levels of components in the LIF signalling pathway, indicating that excessive testosterone may negatively impact endometrial receptivity and potentially affect fertility.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study developed and validated a reliable method to measure finasteride levels in human plasma, which was successfully used to assess its pharmacokinetics after a 5 mg dose in healthy volunteers.

This study concluded that Flaxin tablets and the reference formulation are bioequivalent in terms of absorption rate and extent when administered as a single 5 mg dose to healthy male volunteers.

This study developed a rapid and sensitive method for determining finasteride concentrations in pharmaceuticals, with results comparable to those from the standard HPLC method.

This study optimized and validated a dissolution test method for immediate-release finasteride capsules, highlighting the need for an official standard due to variability in commercial products.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study reviewed contemporary literature and found that combining minoxidil with topical finasteride, biologic adjuvants, or delivery innovations might enhance treatment effectiveness for androgenetic alopecia compared to minoxidil alone, although diverse outcomes and incomplete data limit broader conclusions.

This review discusses treatments for frontal fibrosing alopecia and lichen planopilaris, noting that systemic 5-alpha reductase inhibitors are most effective for stabilization and potential hair regrowth, but reports no new clinical results.

The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.

Researchers developed a quick and sensitive way to measure finasteride in blood using a small sample size.

This study found that a 15% topical minoxidil solution improved hair regrowth in 60% of women with female pattern hair loss who did not respond to the standard 5% solution, without adverse effects.

This study found that finasteride-loaded microemulsions using poloxamer 124 significantly enhanced skin penetration of the drug compared to a standard solution, primarily through targeting hair follicles via the transfollicular pathway, with intercluster, intercellular, and transcellular pathways contributing less.

This study suggests that 5 mg/day oral finasteride may increase hair density and thickness in normoandrogenic Asian women with female pattern hair loss over 12 months.

Finasteride 5mg/day improves hair loss in normoandrogenic Asian women.

Method detects finasteride in plasma and semen with high sensitivity and accuracy.

This study found that taking 1 mg of finasteride daily for male-pattern hair loss significantly reduces serum PSA levels, suggesting similar PSA adjustment is needed as for higher doses during prostate cancer screening.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study observed that coadministration of finasteride and tamsulosin in healthy Chinese males appears unlikely to result in a clinically significant pharmacokinetic interaction.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

High doses of finasteride cause cell growth and tumors in mice.

In this study, 1.25 mg daily finasteride for 28 weeks showed minimal increase in hair density and thickness in normoandrogenic female pattern hair loss, but no significant clinical improvement was observed.

In this study, researchers found that finasteride inhibits progesterone synthesis by blocking cholesterol side-chain cleavage in mouse-derived MA-10 Leydig cells, but this effect may not be evident in human or rat cells.

This article discusses Propecia in dermatology but provides no new research findings.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

In this animal study, finasteride was found to significantly lower cortisol and increase testosterone levels in female rats, indicating its broader impact on endocrine regulation by altering adrenal and gonadal hormones.